Literature DB >> 27662416

GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.

Georgios Christopoulos1, Antonios Vlismas1, Anna Carby2, Stuart Lavery1,2, Geoffrey Trew1,2.   

Abstract

A retrospective, cohort study of high-risk patients undergoing IVF treatment was performed to assess if there is a difference in clinical pregnancy rate, live birth rate and the incidence of ovarian hyperstimulation syndrome, when a GnRH agonist (GnRHa) trigger with intensive luteal support is compared to human chorionic gonadotropin (hCG) with standard luteal support. The control group consisted of 382 high-risk patients having a GnRH antagonist protocol with 194 receiving an hCG trigger. All patients had ≥18 follicles ≥11mm or serum oestradiol >18,000pmol/l on the day of trigger. Patients had a single or double embryo transfer at cleavage or blastocyst stage. Logistic regression was used to adjust for differences between the groups. An intention-to-treat analysis of all cycles was performed. No statistically significant differences were observed in terms of positive pregnancy test, clinical pregnancy rate and live birth rate. Only one patient (0.3%) was hospitalized with severe OHSS in the GnRHa group, compared to 26 patients (13%) in the hCG group. In conclusion, GnRHa trigger is associated with similar pregnancy rates with hCG trigger and a significant reduction in hospitalization for severe OHSS after an intention to treat analysis was performed.

Entities:  

Keywords:  GnRH agonist; IVF; buserelin; hCG; ovarian hyperstimulation syndrome

Mesh:

Substances:

Year:  2016        PMID: 27662416     DOI: 10.1080/14647273.2016.1217432

Source DB:  PubMed          Journal:  Hum Fertil (Camb)        ISSN: 1464-7273            Impact factor:   2.767


  1 in total

1.  Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturation-A Retrospective Proof-of-Concept Study.

Authors:  Barbara Lawrenz; Suzan Samir; Nicolas Garrido; Laura Melado; Nils Engelmann; Human M Fatemi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-15       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.